Tag Archives: Biotech

A new gene therapy approved!

This week GSK’s ex vivo gene therapy for ADA-SCID received its marketing authorization from the European Medicine Agency. This is awesome news for the medical world and patients.


Continue reading

Bioscience Enterprise Forum – PharmaVentures


PharmaVentures  [www.pharmaventures.com] provide valuation, strategy, market insight and transaction services to the health care industry. 80% of their clients are from outside the UK . Tonight we had Finton Walton (CEO) speak to the forum about ‘ deal making in a risk averse environment for success…’. logo

Tonight’s notes:

  • tough to raise money now because we are in a risk averse environment
  • pharma experiencing patent cliff meaning a sudden drop in revenue is looming. Therefore decreasing R&D spend.
  • regulations and reimbursement is getting tougher
  • leading to fewer pharma companies that spend less = less partnering opportunities
  • deal making is making a recovery since GFC
  • collaboration R&D deals are declining
  • but big pharma still interested in early stage R&D – of interest to NZ
  • average deal value is decreasing
  • option-based deals reduce the risk for the license (capital linked to milestones). GSK tops the pharmas with respect to performing option-based deals. Amgen and AstraZeneca have the lowest levels.
  • only 12% of options are exercised within the first 2 years
  • pharma are worried about deals = competition is fierce
  • before GFC M&As involving spinouts or emerging companies were on the decline, now they are increasing
  • contingent value rights are options for shareholders of an acquired company
  • plan your company exit from the beginning. Forget IPOS, get to know your buys early on.
  • Pharmas looking to move research close to where the science is i.e. universities and institutes = more partnerships on the way
  • NBI (NASDAQ Biotech Index) out performs the NASDAQ even more so since GFC.
  • Finton mentioned that NZ has all the ingredients to attract foreign investment.


Graeme @ graemefielder.com

Update in Biotech & Biz


Being overseas for most of the year and removed from much of the happenings of the rest of the world I’ve missed out on a lot of biotech and biz start-up news. Here are the main things I have caught up with to date:

  1. The Dendreon/ Provenge screw up.
  2. Gilead buys Genentech’s biologics manufacturing facility.
  3. Google buys Motorola Mobility and Google Plus is launched.
  4. Roche melanoma blockbuster.
  5. Australian R&D tax credit.
  6. Cancer killing virus.
  7. Start-up America launches. 
  8. Peter Thiel – funds college kids to quit college. And another article opposing the idea.
  9. 2011 Fierce 15 Biotech Companies.
  10. Techstars TV goes live.
  11. Patent reform bill gets approval.
  12. Genentech breast cancer drug looks promising.
  13.   Harvard life sciences accelerator. 
  14. Low participation rates in cancer trials.
  15. Genetic screening of 9000 tumours.


For more local developments:

  1. Squid Gel a commercial success.
  2. MSI – Fast track for digital entrepreneurs.
  3. MSI – undergrad summer internship fellowships.
  4. The San Fran Launch Pad. http://www.klp.org.nz/
  5. The Spark $100k Challenge Finalists.
  6. The Unlimited Investment Challenge Finalists.
  7. E&Y Entrepreneur of Year Finalists.
  8. ICE Ideas Conference & 3000.org.nz.
  9. Rob Adams in NZ. Article.
  10. Peter Thiel in NZ . ICE ideas conference.
  11.   Steve Blank coming to NZ.
  12.   Start up weekends.
  13.   Xero & Orion – mass hire. Media article here.
  14.   RWC activities – The Rutherford innovation show case & NZBIO showcasing NZs clinical trial expertise. Also tech trade & investment forum.
  15. Idealog’s MSI-sponsored Guide to Innovation
  16.   Auckland City’s Development Plan for ‘ Creating the world’s most liveable city’.
  17.   Right Hemisphere acquired by SAP.



Graeme @ graemefielder.com


Just some light summer reading for you:

  • UniSeed, a new aussie investment fund
  • The entrepreneurial mind
  • Ten reasons by university spin-offs fail
  • Steve Burrill’s 2011 predictions for biotech
  • The Crunchies – 2010’s top start-ups. Take some time to explore the winners and nominees.
  • Creating an App – came across a good how to guide for those looking at developing an app.
  • Anti tumour effects of endothelial cells discovered.
  • 21 drugs in 2010
  • Journal access handicaps small biotechs.



Graeme @ graemefielder.com

Two Biotech Jobs

Biotech jobs in NZ are rare to come by so just thought I’d post these to spread the word:

  1. Senior Materials Scientist http://www.seek.co.nz/job/b-senior-b-b-materials-b-b-scientist-b/auckland/17573357/101/1/ . At Living Cell Technologies would be my guess.
  2. Process Engineer/ Biotechnologist – Fermentation industry.  http://www.seek.co.nz/job/process-engineer-biotecnologist-b-fermentation-b-industry/auckland-inner/17576554/102/1/. My guess would be at Lanzatech



Graeme @ graemefielder.com